Ironwood Pharmaceuticals (NASDAQ:IRWD) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen cut shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a strong-buy rating to a buy rating in a research report report published on Saturday.

IRWD has been the subject of several other reports. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.23.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD opened at $4.32 on Friday. The business’s 50-day moving average is $3.90 and its two-hundred day moving average is $3.97. The company has a market capitalization of $704.42 million, a P/E ratio of 5.61 and a beta of 0.20. Ironwood Pharmaceuticals has a fifty-two week low of $0.81 and a fifty-two week high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The company had revenue of $113.04 million during the quarter, compared to analysts’ expectations of $114.84 million. Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%. Analysts forecast that Ironwood Pharmaceuticals will post 1.04 EPS for the current year.

Insider Activity at Ironwood Pharmaceuticals

In other news, Director Julie Mchugh sold 21,571 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total value of $80,459.83. Following the transaction, the director owned 250,749 shares in the company, valued at $935,293.77. This trade represents a 7.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total value of $578,062.80. Following the completion of the sale, the insider directly owned 313,680 shares in the company, valued at $1,417,833.60. This represents a 28.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 9.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in Ironwood Pharmaceuticals during the 2nd quarter worth $2,142,000. Pacer Advisors Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at about $3,982,000. Segall Bryant & Hamill LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at about $976,000. Bull Harbor Capital LLC purchased a new position in shares of Ironwood Pharmaceuticals in the first quarter worth about $48,000. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Ironwood Pharmaceuticals by 48.7% in the first quarter. EverSource Wealth Advisors LLC now owns 20,336 shares of the biotechnology company’s stock worth $71,000 after buying an additional 6,656 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.